daohang fenxiangbox searchbox qikanlogonew daohangnew searchboxnew navrightzone footerzone paper

Immunostimulatory multi-interfacial bimetallic phosphide nanoparticles as photo-enhanced cascade nanozyme for cancer therapy AITranslate

University of Chinese Academy of Sciences; University of Chinese Academy of Sciences; University of Chinese Academy of Sciences;Beijing Institute of Nanoenergy and Nanosystems;Beijing Institute of Nanoenergy and Nanosystems;Beijing Institute of Nanoenergy and Nanosystems;Beijing Institute of Nanoenergy and Nanosystems; University of Melbourne; University of Chinese Academy of Sciences; University of Chinese Academy of Sciences
AITranslate
Publisher: Elsevier
Share Citation Information Add to Favorites

    Scan to share on WeChat or Moments

Use WeChat scan.
Share with WeChat friends or Moments

Abstract AITranslate

Nanozyme has been widely explored for tumor catalytic therapy. Nevertheless, highly efficient and specific cancer therapy with nanozyme is still challenging under the strict condition of tumor microenvironment (TME). Herein, we fabricate a bimetallic phosphide nanoparticle (CuFeP) with multiphase interfaces as a photo-enhanced cascade nanozyme for efficient immunostimulatory cancer therapy. The CuFeP has structural, atomic and electric coupling with multi-interfacial heterojunction to promote the interfacial electron transfer, and the bimetallic redox couple of Cu+/2+ and Fe0/2+/3+ to synergistically improve the cascade catalysis of peroxidase (POD) and glutathione peroxidase (GPX), thereby inducing lethal cellular oxidative damage. Moreover, the excellent photothermal efficiency of 66.9% assists in catalysis in view of thermodynamics. Finally, the synergetic catalysis triggers immune cell death (ICD) process, which promotes maturation of dendritic cells (DCs), activation of cytotoxic and helper T cells, and excretion of proinflammatory cytokines to boost antitumor immunity in vivo. This study provides an enlightenment for the design of efficient therapeutic nanozyme to conquer cancer.

KeyWords AITranslate

No data

Basic Information:

DOI:https://doi.org/10.1016/j.apmt.2021.101255

Chinese Library Classification Number:

Citation Information:

Nanozyme has been widely explored for tumor catalytic therapy. Nevertheless, highly efficient and specific cancer therapy with nanozyme is still challenging under the strict condition of tumor microenvironment (TME). Herein, we fabricate a bimetallic phosphide nanoparticle (CuFeP) with multiphase interfaces as a photo-enhanced cascade nanozyme for efficient immunostimulatory cancer therapy. The CuFeP has structural, atomic and electric coupling with multi-interfacial heterojunction to promote the interfacial electron transfer, and the bimetallic redox couple of Cu+/2+ and Fe0/2+/3+ to synergistically improve the cascade catalysis of peroxidase (POD) and glutathione peroxidase (GPX), thereby inducing lethal cellular oxidative damage. Moreover, the excellent photothermal efficiency of 66.9% assists in catalysis in view of thermodynamics. Finally, the synergetic catalysis triggers immune cell death (ICD) process, which promotes maturation of dendritic cells (DCs), activation of cytotoxic and helper T cells, and excretion of proinflammatory cytokines to boost antitumor immunity in vivo. This study provides an enlightenment for the design of efficient therapeutic nanozyme to conquer cancer.

quote

GB/T 7714-2015 [1] Xingru Zhao, Shuncheng Yao, Xingyi Wan, et al. Applied Materials Today, 2021(25). DOI:10.1016/j.apmt.2021.101255.
MLA [1] Xingru Zhao, et al., Applied Materials Today, no. 25, 2021, https://doi.org/10.1016/j.apmt.2021.101255.
APA [1] Xingru Zhao, Shuncheng Yao, Xingyi Wan, Tian Huang, Zeyu Zhang, Xueyu Wang, Shaobo Wang, Qinghua Liang, Zhou Li, & Linlin Li. (2021). Applied Materials Today(25). https://doi.org/10.1016/j.apmt.2021.101255
IEEE [1] Xingru Zhao, Shuncheng Yao, Xingyi Wan, Tian Huang, Zeyu Zhang, Xueyu Wang, Shaobo Wang, Qinghua Liang, Zhou Li, and Linlin Li, Applied Materials Today, no. 25, 2021, doi: 10.1016/j.apmt.2021.101255.